RHHBF - Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

2024-04-17 13:26:56 ET

Summary

• Tempest Therapeutics, Inc. achieved positive results from phase 1b/2 study using TPST-1120 + Tecentriq + Avastin for the treatment of patients with 1st-line HCC; Significant improvements in both confirmed and unconfirmed responses.
• Updated results from the phase 1b/2 study, using TPST-1120 + Tecentriq + Avastin for the treatment of patients with 1st-line HCC, are expected in 2024.
• It is expected that the global liver cancer drug market size is expected to reach $7.6 billion by 2033.
• TPST-1495 is another clinical product in its pipeline that is being explored in a phase 1/2 study for the treatment of patients with advanced endometrial cancer; Data from this study using the two highest dose combination cohorts to be released in 2024.

Tempest Therapeutics, Inc. ( TPST ) has been able to make significant progress in advancing the use of its lead drug TPST-1120 for the treatment of patients with advanced solid tumors. In particular, it was able to achieve positive results as it relates to the advancement of this drug in combination with standard of care [SOC] atezolizumab and bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma [HCC]. Matter of fact, a phase 1/2 study already proved that the addition of TPST-1120 together with SOC for this patient population was able to beat out SOC alone....

For further details see: